Summary
Global Markets Direct’s, ‘Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016’, provides an overview of the Alnylam Pharmaceuticals, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.
- The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Alnylam Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Alnylam Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Alnylam Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Alnylam Pharmaceuticals, Inc. Snapshot 6
Alnylam Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Alnylam Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Alnylam Pharmaceuticals, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance 14
Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Alnylam Pharmaceuticals, Inc. - Drug Profiles 19
patisiran 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
revusiran 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ALN-PCSsc 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
fitusiran 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ALN-AAT 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ALN-CC5 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ALN-GO1 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ALN-HBV 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ALN-AS1 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ALN-TTRsc02 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ALN-VSP 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ALN-AC3 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ALN-AGT 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ALN-ANG 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ALN-PDL 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ALN-TMP 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Cellular Immunotherapy for Oncology and Viral Infections 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ALN-HDV 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
RNAi Oligonucleotide for Undisclosed Indication 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
RNAi Oligonucleotides for Genetic Diseases 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RNAi Oligonucleotides for Hepatic Infections 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Alnylam Pharmaceuticals, Inc. - Pipeline Analysis 49
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target 49
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 51
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 52
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 53
Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates 55
Alnylam Pharmaceuticals, Inc. - Dormant Projects 83
Alnylam Pharmaceuticals, Inc. - Company Statement 84
Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries 86
Head Office 86
Other Locations & Subsidiaries 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88
List of Tables
Alnylam Pharmaceuticals, Inc., Key Information 6
Alnylam Pharmaceuticals, Inc., Key Facts 6
Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2016 8
Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10
Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11
Alnylam Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 12
Alnylam Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13
Alnylam Pharmaceuticals, Inc. - Phase III, 2016 14
Alnylam Pharmaceuticals, Inc. - Phase II, 2016 15
Alnylam Pharmaceuticals, Inc. - Phase I, 2016 16
Alnylam Pharmaceuticals, Inc. - Preclinical, 2016 17
Alnylam Pharmaceuticals, Inc. - Discovery, 2016 18
Alnylam Pharmaceuticals, Inc. - Pipeline by Target, 2016 49
Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 51
Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 52
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 53
Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 55
Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 83
Alnylam Pharmaceuticals, Inc., Subsidiaries 86
List of Figures
Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 8
Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10
Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11
Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016 49
Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 51
Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 52
Alnylam Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 53
